Free tool
Drug Trial Radar: Pain and anesthesia
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
39
Recruiting, industry sponsors, Pain and anesthesia, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed755
39 trials
Showing 1 to 25, recently updated first.
- A Study to Evaluate the Safety and Pain Relief of MAX-001 After Surgical Removal of Wisdom TeethPivotal-lookingRecruiting
Maxona Pharmaceuticals, Inc.Industry
NCT07937657 · 276 participants (planned) · Start Nov 10, 2026 · Primary completion Jun 2027
Drug: MAX-001; Placebo · For: Impacted Third Molar Tooth; Tooth Extraction Status Nos
Sites: Salt Lake City, Utah
argenxargenx (ARGX)
NCT07760818 · 75 participants (planned) · Start Oct 9, 2026 · Primary completion Jul 28, 2028
Drug: efgartigimod PH20 SC · For: Sjogrens Disease; Primary Sjögren's Syndrome Painful Sensory Neuropathies
Sites: Sarasota, Florida; Tampa, Florida; Sterling Heights, Michigan
- A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07862595 · 380 participants (planned) · Start Nov 2, 2026 · Primary completion Jun 10, 2027
Drug: MK-6916; Hydrocodone/acetaminophen (HB/APAP) and 2 more · For: Pain Management
Sites: Miami, Florida; Tampa, Florida; Atlanta, Georgia · 9 sites in all
- The Efficacy and Safety of DLBS1442 in Patients With Primary DysmenorrheaPivotal-lookingRecruiting
Dexa Medica GroupIndustry
NCT07937462 · 210 participants (planned) · Start Aug 1, 2026 · Primary completion Dec 2026
Drug: DLBS1442; Placebo · For: Primary Dysmenorrhea
Sites: Jakarta, Indonesia
- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07830329 · 300 participants (planned) · Start Oct 29, 2026 · Primary completion Nov 24, 2028
Drug: Olatorepatide; Placebo · For: Hidradenitis Suppurativa
Sites: The Bronx, New York
- A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) PeriodPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07748624 · 120 participants (planned) · Start Oct 30, 2026 · Primary completion Dec 26, 2028
Drug: Arumakimig; Placebo and 1 more · For: VEXAS Syndrome
Sites: Yokohama, Japan; Suita, Japan; Hachiōji, Japan · 6 sites in all
- A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic PainPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05986292 · 10,000 participants (planned) · Start Jan 30, 2020 · Primary completion Apr 2027
Drug: LY3016859 ISA; LY3556050 ISA and 5 more · For: Osteoarthritis, Knee; Diabetic Neuropathic Pain; Chronic Low-back Pain
Sites: Birmingham, Alabama; Glendale, Arizona; Phoenix, Arizona · 64 sites in all
- A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis PainPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07641517 · 150 participants (planned) · Start Jun 25, 2026 · Primary completion Apr 2027
Drug: LY4065967; Placebo · For: Osteoarthritis, Knee; Chronic Pain
Sites: Birmingham, Alabama; Phoenix, Arizona; Palm Springs, California · 36 sites in all
- A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic PainPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07285018 · 150 participants (planned) · Start Feb 16, 2026 · Primary completion Jul 2027
Drug: LY4065967; Placebo · For: Diabetic Peripheral Neuropathic Pain
Sites: Birmingham, Alabama; Phoenix, Arizona; Palm Springs, California · 36 sites in all
- A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back PainPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07641504 · 150 participants (planned) · Start Aug 12, 2026 · Primary completion Apr 2027
Drug: LY4065967; Placebo · For: Chronic Pain; Low Back Pain
Sites: Birmingham, Alabama; Phoenix, Arizona; Palm Springs, California · 36 sites in all
Cytogel Pharma, LLCIndustry
NCT07905105 · 32 participants (planned) · Start Sep 25, 2026 · Primary completion Oct 2027
Drug: CYT-1010; Placebo · For: Acute Postoperative Pain; Dental Pain
Sites: Salt Lake City, Utah
Adneuris Therapeutics, Inc.Industry
NCT07874620 · 45 participants (planned) · Start Oct 2026 · Primary completion Mar 2027
Drug: Cebranopadol; Cebranopadol and 1 more · For: Chronic Pain; Pain; Opioid Withdrawal (Disorder) and 1 more
Sites: North Canton, Ohio; Houston, Texas
VM Therapeutics LLCIndustry
NCT07072468 · 16 participants (planned) · Start Dec 12, 2025 · Primary completion Jun 30, 2027
Drug: VMD-3866 Gel; Placebo Gel · For: Chemotherapy-induced Peripheral Neuropathy; Chemotherapy-induced Neuropathic Pain; CIPN - Chemotherapy-Induced Peripheral Neuropathy and 14 more
Sites: London, United Kingdom
Azure Biotech Inc.Industry
NCT06197568 · 90 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 31, 2026
Drug: Lasofoxifene Tartrate · For: Vulvo Vaginal Atrophy (VVA)
Sites: Saint Paul, Minnesota
- Evaluation of Intra-articular CX-011 to Treat Moderate to Severe Pain From Knee OsteoarthritisRecruiting
CarthroniX, Inc.Industry
NCT07308834 · 72 participants (planned) · Start Aug 11, 2026 · Primary completion Oct 30, 2028
Drug: CX-011 · For: Osteoarthritis of the Knees
Sites: Los Angeles, California
- A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the KneePivotal-lookingRecruiting
Pacira Pharmaceuticals, IncIndustry
NCT06884865 · 135 participants (planned) · Start Feb 26, 2025 · Primary completion Nov 2026
Drug: Enekinragene Inzadenovec (PCRX-201); Placebo · For: Osteoarthritis (OA) of the Knee
Sites: Birmingham, Alabama; Phoenix, Arizona; Beverly Hills, California · 40 sites in all
- A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic NeuralgiaPivotal-lookingRecruiting
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Industry
NCT07758920 · 200 participants (planned) · Start Aug 2026 · Primary completion Jun 2027
Drug: HL-1186; HL-1186 placebo and 2 more · For: Postherpetic Neuralgia ( PHN )
Sites: Beijing, China
- Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal SurgeryPivotal-lookingRecruiting
Shanghai Huilun Pharmaceutical Co., Ltd.Industry
NCT07709598 · 330 participants (planned) · Start May 11, 2026 · Primary completion Oct 2026
Drug: HL-1186; HL-1186 placebo and 2 more · For: Postoperative Pain
Sites: Chengdu, China
- Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic SurgeryPivotal-lookingRecruiting
Shanghai Huilun Pharmaceutical Co., Ltd.Industry
NCT07699601 · 330 participants (planned) · Start May 9, 2026 · Primary completion Oct 2026
Drug: HL-1186; HL-1186 placebo and 2 more · For: Postoperative Pain
Sites: Changsha, China
Clarent Biopharma, Inc.Industry
NCT07687966 · 80 participants (planned) · Start May 8, 2026 · Primary completion Jun 30, 2026
Drug: CBP-0276; Placebo for CBP-0276 · For: Hip or Knee Replacement
Sites: Mexico City, Mexico
- Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06619860 · 300 participants (planned) · Start Oct 18, 2024 · Primary completion Mar 25, 2027
Drug: VX-993; Pregabalin and 2 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Cullman, Alabama; Bakersfield, California; La Mesa, California · 47 sites in all
- A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal SurgeryPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07533786 · 200 participants (planned) · Start May 22, 2026 · Primary completion Nov 22, 2026
Drug: HSK55718 dose level1; HSK55718 dose level2 and 3 more · For: Pain After Surgery
Sites: Changsha, China; Chengdu, China
- Y-4 to Treat the Postherpetic NeuralgiaPivotal-lookingRecruiting
Neurodawn Pharmaceutical Co., Ltd.Industry
NCT07275762 · 160 participants (planned) · Start Feb 2, 2026 · Primary completion Jul 31, 2026
Drug: Y-4 tables; Pregabalin · For: Postherpetic Neuralgia; Y-4; Pregabalin
Sites: Nanjing, China
Rebel Medicine IncIndustry
NCT07574385 · 60 participants (planned) · Start Mar 10, 2026 · Primary completion Aug 2026
Drug: ALX006 (bupivacaine extended-release injection); Bupivacaine Hcl 0.25% Inj · For: Hallux Valgus; Bunionectomy
Sites: Millcreek, Utah
- A Study of LY4515100 in Participants With Pain Following Third Molar RemovalPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07511816 · 212 participants (planned) · Start Apr 1, 2026 · Primary completion Nov 2026
Drug: LY4515100; Placebo · For: Acute Pain; Molar; Molar, Third and 1 more
Sites: Salt Lake City, Utah
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.